Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib …

D Schadendorf, A Hauschild, M Santinami… - The Lancet …, 2019 - thelancet.com
Background In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with
BRAF V600E or BRAF V600K mutations received adjuvant dabrafenib plus trametinib or …
被引用次数：47 相关文章

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib …

D Schadendorf, A Hauschild… - The Lancet …, 2019 - pubmed.ncbi.nlm.nih.gov
Background In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with
BRAF V600E or BRAF V600K mutations received adjuvant dabrafenib plus trametinib or …

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF or BRAF mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD) …

D Schadendorf, A Hauschild, M Santinami… - Lancet …, 2019 - zora.uzh.ch
BACKGROUND In the phase 3 COMBI-AD study, patients with resected, stage III melanoma
with BRAF or BRAF mutations received adjuvant dabrafenib plus trametinib or placebo. The …

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib …

D Schadendorf, A Hauschild, M Santinami… - The Lancet …, 2019 - research.monash.edu
Background: In the phase 3 COMBI-AD study, patients with resected, stage III melanoma
with BRAF V600E or BRAF V600K mutations received adjuvant dabrafenib plus trametinib …

[引用][C] Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus …

D Schadendorf, A Hauschild… - The Lancet …, 2019 - espace.library.uq.edu.au
Background: In the phase 3 COMBI-AD study, patients with resected, stage III melanoma
with BRAF or BRAF mutations received adjuvant dabrafenib plus trametinib or placebo. The …
[PDF] academia.edu

[PDF][PDF] Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus …

D Schadendorf, A Hauschild, M Santinami, V Atkinson… - 2019 - academia.edu
Background In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with
BRAFV600E or BRAFV600K mutations received adjuvant dabrafenib plus trametinib or …

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib …

D Schadendorf, A Hauschild, M Santinami… - The Lancet …, 2019 - thelancet.com
Background In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with
BRAF V600E or BRAF V600K mutations received adjuvant dabrafenib plus trametinib or …

[引用][C] Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF (V600E) or BRAF (V600K) mutations treated with adjuvant dabrafenib plus …

D Schadendorf, A Hauschild, M Santinami… - THE LANCET …, 2019 - research.unipg.it
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF(V600E) or
BRAF(V600K) mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a …

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib …

D Schadendorf, A Hauschild… - The Lancet …, 2019 - researchers.mq.edu.au
Background: In the phase 3 COMBI-AD study, patients with resected, stage III melanoma
with BRAF V600E or BRAF V600K mutations received adjuvant dabrafenib plus trametinib …

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus …

D Schadendorf, A Hauschild, M Santinami… - The Lancet …, 2019 - eprints.ncl.ac.uk
Abstract© 2019 Elsevier Ltd Background: In the phase 3 COMBI-AD study, patients with
resected, stage III melanoma with BRAF V600E or BRAF V600K mutations received …